Effect of volunteers on maize gene flow

Palaudelmàs, Montserrat; Peñas, Gisela; Melé, Enric; Serra, Joan Mayol; Salvia, Jordi; Pla, María; Nadal, Anna; Messeguer, Joaquima

doi:10.1007/s11248-009-9250-7

Cited by 97 publications

(88 citation statements)

References 9 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Field observations performed on maize volunteers after GM maize cultivation in Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that crosspollinated neighbour plants at low levels (Palaudelmàs et al, 2009).…”

Section: Potential For Gene Transfermentioning

confidence: 99%

Scientific Opinion on the application (EFSA‐GMO‐BE‐2012‐110) for the placing on the market of tissue‐selective herbicide‐tolerant genetically modified maize MON 87427 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto

2015

EFS2

View full text Add to dashboard Cite

Maize MON 87427 was developed by Agrobacterium tumefaciens-mediated transformation to express the CP4 5-enolpyruvyl-shikimate-3-phosphate synthase (EPSPS) protein, in all tissues except for the male reproductive tissues, conferring tissue-selective tolerance to glyphosate. The molecular characterisation of maize MON 87427 did not give rise to safety issues. Agronomic and phenotypic characteristics as well as compositional data of maize MON 87427 did not raise food/feed and environmental safety concerns. No differences in the compositional data requiring further safety assessment were identified. There were no concerns regarding the potential toxicity and allergenicity of the newly expressed CP4 EPSPS protein. The nutritional value of maize MON 87427 is not expected to differ from that of non-genetically modified (GM) maize varieties. There are no indications of an increased likelihood of establishment or spread of feral maize plants. Given its intended use in food and feed, interactions with the biotic and abiotic environment were not considered an issue. Risks associated with an unlikely, but theoretically possible, horizontal gene transfer from maize MON 87427 to bacteria have not been identified. The monitoring plan and reporting intervals are in line with the scope of the application for maize MON 87427. In conclusion, the EFSA Panel on Genetically Modified Organisms considers that the information available for maize MON 87427 addresses the scientific comments raised by Member States and that the maize MON 87427, as described in this application, is as safe as its conventional counterpart and non-GM reference varieties with respect to potential effects on human and animal health and the environment in the context of the scope of the application.

show abstract

Section: Potential For Gene Transfermentioning

confidence: 99%

Scientific Opinion on the application (EFSA‐GMO‐BE‐2012‐110) for the placing on the market of tissue‐selective herbicide‐tolerant genetically modified maize MON 87427 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto

2015

EFS2

View full text Add to dashboard Cite

show abstract

“…Field observations on maize volunteers after GM maize cultivation in Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that crosspollinated neighbour plants only at low levels (Palaudelmàs et al, 2009). …”

Section: (Iv) Risk Conclusionmentioning

confidence: 99%

Scientific Opinion on an application (EFSA-GMO-NL-2009-70) for the placing on the market of genetically modified drought tolerant maize MON 87460 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto

2012

EFSA Journal

View full text Add to dashboard Cite

Maize MON 87460 was developed through Agrobacterium-mediated transformation and expresses the cold shock protein B (CspB) from Bacillus subtilis and neomycin phosphotransferase II (NPTII) from Escherichia coli to reduce yield loss under water-limited conditions. Maize MON 87460 contains a single copy of the cspB and nptII expression cassettes. Bioinformatic analysis of the flanking sequences and the open reading frames spanning the junctions created by the transformation did not raise safety issues. Comparative analyses established that, besides the expression of the CspB and NPTII proteins, some differences were observed in the composition of forage and grain produced from maize MON 87460 compared with its conventional counterpart, when grown under well-watered conditions. Given the magnitude of these changes and the characteristics of these endpoints, the EFSA GMO Panel concluded that the observed differences do not raise safety concerns for humans and animals. Under stressful conditions, maize MON 87460 can show enhanced agronomic performance characteristics and some differences in chemical composition in comparison with its conventional counterpart. Given the intended trait, the observed differences were not unexpected, and did indicate no safety concerns. The safety assessment identified no concerns regarding the potential toxicity and allergenicity of the CspB and NPTII proteins, or of maize MON 87460. Maize MON 87460 is as nutritious as any other maize and can be used in the same way. In delivering its Scientific Opinion, the EFSA GMO Panel considered: the application EFSA-GMO-NL-2009-70; additional information supplied by the applicant; scientific comments submitted by the Member States; and relevant scientific publications.The EFSA GMO Panel evaluated maize MON 87460 with reference to the intended uses and principles described in its risk assessment and monitoring guidelines. The scientific evaluation of the risk assessment included molecular characterisation of the inserted DNA and expression of the target proteins. An evaluation of the comparative analysis of composition and agronomic and phenotypic traits was undertaken, and the safety of the newly expressed proteins and the whole food/feed were evaluated with respect to potential toxicity, allergenicity and nutritional quality. An evaluation of environmental impacts and of the post-market environmental monitoring plan was undertaken.Maize MON 87460 was developed through Agrobacterium-mediated transformation and expresses the cold shock protein B (CspB) from Bacillus subtilis and neomycin phosphotransferase II (NPTII) from Tn5 of Escherichia coli. Maize MON 87460 was developed to provide reduced yield loss under conditions in which water is limited compared with conventional maize. The CspB protein is an RNA chaperone associated with enhanced abiotic stress tolerance in bacteria and plants, through its interaction with RNA secondary structures, limiting their misfolding and allowing cells to maintain cellular functions under various stress co...

show abstract

“…The survival of maize is limited by a combination of low competitiveness, absence of a dormancy phase, and susceptibility to plant pathogens, herbivory and cold climate conditions. Maize plants are only winter hardy in European regions with mild winters, and in those situations maize kernels remaining in the field after harvest can germinate, grow, flower, and locally cross-pollinate neighbouring maize plants Palaudelmàs et al, 2009). Despite cultivation for centuries, maize plants do not occur outside cultivated or disturbed land in Europe.…”

Section: Unintended Effects On Plant Fitness Due To the Genetic Modifmentioning

confidence: 99%

Applications (EFSA‐GMO‐RX‐MON810) for renewal of authorisation for the continued marketing of (1) existing food and food ingredients produced from genetically modified insect resistant maize MON810; (2) feed consisting of and/or containing maize MON810, including the use of seed for cultivation; and of (3) food and feed additives, and feed materials produced from maize MON810, all under Regulation (EC) No 1829/2003 from Monsanto

2009

EFS2

View full text Add to dashboard Cite

SUMMARYThis document provides a scientific opinion of the Scientific Panel on Genetically Modified Organisms (GMO Panel) of the European Food Safety Authority (EFSA) on 3 applications 1 For citation purposes: Scientific Opinion of the Panel on Genetically Modified Organisms on applications (EFSA-GMO-RX-MON810) for the renewal of authorisation for the continued marketing of (1) existing food and food ingredients produced from genetically modified insect resistant maize MON810; (2) feed consisting of and/or containing maize MON810, including the use of seed for cultivation; and of (3) (1) existing food and food ingredients produced from genetically modified (GM) maize MON810 (Unique Identifier MON-ØØ81Ø-6); (2) feed consisting of and/or containing maize MON810, including the use of seed for cultivation; and of (3) food and feed additives, and feed materials produced from maize MON810, developed by Monsanto to provide resistance to lepidopteran target pests.The scopes of the 3 renewal applications cover the continued marketing of:-existing food and food ingredients produced from maize MON810 (Reference EFSA-GMO-RX-MON810 [8-1a] ) that have been placed on the market in accordance with [20-1a] );-food additives produced from maize MON810 that were authorised under Directive 89/107/EEC, and feed produced from maize MON810, i.e., feed additives lawfully placed on the market under Directive 70/524/EEC and feed materials (Reference EFSA-GMO-RX-MON810 [8-1b/20-1b] ).After the date of entry into force of the Regulation (EC) No 1829/2003, the products mentioned above were notified to the European Commission according to Articles 8 or 20 of this Regulation and subsequently included in the Community Register of GM food and feed.Maize MON810 expresses a Cry1Ab insecticidal protein, derived from Bacillus thuringiensis subsp. kurstaki, which confers protection against lepidopteran target pests such as the European corn borer (Ostrinia nubilalis) and species belonging to the genus Sesamia.In delivering its scientific opinion, the EFSA GMO The EFSA GMO Panel assessed maize MON810 with reference to the intended uses and appropriate principles described in the guidance document of the EFSA GMO Panel for the risk assessment of GM plants and derived food and feed. The scientific assessment included molecular characterisation of the inserted DNA and expression of target proteins. A comparative analysis of agronomic traits and composition was undertaken, and the safety of the new protein and the whole food/feed were evaluated with respect to potential toxicity, allergenicity and nutritional quality. An assessment of environmental impacts and the postmarket environmental monitoring plan were undertaken.Maize MON810 was generated by particle acceleration technology. Maize MON810 expresses a cry1Ab coding sequence that encodes an insecticidally active Cry1Ab protein. The molecular characterisation data established that a single insert is integrated in the maize The expression of the genes introduced by genetic modification has been su...

show abstract

Effect of volunteers on maize gene flow

Cited by 97 publications

References 9 publications

Scientific Opinion on the application (EFSA‐GMO‐BE‐2012‐110) for the placing on the market of tissue‐selective herbicide‐tolerant genetically modified maize MON 87427 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto

Scientific Opinion on the application (EFSA‐GMO‐BE‐2012‐110) for the placing on the market of tissue‐selective herbicide‐tolerant genetically modified maize MON 87427 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto

Scientific Opinion on an application (EFSA-GMO-NL-2009-70) for the placing on the market of genetically modified drought tolerant maize MON 87460 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto

Contact Info

Product

Resources

About